Drugs / T-DXd combined with immune checkpoint inhibitor
T-DXd combined with immune checkpoint inhibitor
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06733233 | Jan 2025 → Jan 2028 expected | estrogen-receptor positive breast cancer | Guangzhou Women and Children's Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-DXd combined with immune checkpoint inhibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06733233 ↗ |
| Modality | Other / unclassified | “immune checkpoint inhibitor” NCT06733233 ↗ |
| Route | Intravenous | “Teraplizumab (240 mg/kg i.v. q3w)” NCT06733233 ↗ |